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Background: Registration authorities evaluate effects of new medicines for chronic
obstructive pulmonary disease (COPD) on airway obstruction, dyspnea, health status
and exacerbations. To establish clinical relevance, minimal clinically important differences
(MCIDs) are used. The aim of this study was to investigate which efficacy endpoints and
MCIDs healthcare professionals consider clinically relevant for new COPD medicines.
Materials and Methods: 7,731 Healthcare professionals received an electronic
questionnaire. Participants were asked for: 1) preferred efficacy endpoints for new
COPD medicines and 2) cut-off values defining clinical relevance for forced expiratory
volume in 1 sec (FEV1), Transition Dyspnea Index (TDI) and St. George’s Respiratory
Questionnaire (SGRQ). Those cut-off values were compared to the MCIDs used by
registration authorities, namely 100 ml for FEV1, 1 unit for TDI and 4 units for SGRQ.
Results: 227 Healthcare professionals responded to the questionnaire. Most preferred
efficacy endpoints were exacerbations (51.0%), airway obstruction (46.9%) and health
status (44.9%). Mean cut-off values for TDI and SGRQ were significantly higher than the
corresponding MCIDs, mean differences 1.5 (95%CI = 1.3–1.8, p < 0.001) and 7.0 (95%
CI = 5.1–8.8, p < 0.001), respectively. The mean cut-off value for FEV1 was comparable to
the MCID (mean difference 2.2, 95%CI = -19.9–24.3, p = 0.84).
Conclusions: Healthcare professionals largely agree with efficacy endpoints used for the
evaluation of new COPDmedicines. However, they seem to prefer higher cut-off values for
clinical relevance for TDI and SGRQ than the registration authorities. Effects of newin.org February 2020 | Volume 10 | Article 15191
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Frontiers in Pharmacology | www.frontiersmedicines on TDI and SGRQ that are considered clinically relevant by registration
authorities do, therefore, not necessarily reflect healthcare professionals’ perspectives
on clinical relevance.Keywords: clinical relevance, minimal clinically important differences, patient-reported outcomes, chronic
obstructive pulmonary disease, new medicine, forced expiratory volume in 1 sec, St. George’s Respiratory
Questionnaire, Transition Dyspnea IndexINTRODUCTION
New medicines are evaluated by registration authorities in order
to assess their benefit-risk balance. The assessment of clinical
relevance of new medicines by the registration authorities
depends heavily on clinical trials. A common approach in
clinical trials to investigate clinical effects is the use of patient-
reported outcomes (PROs) (Hedayat et al., 2015). PROs
represent the patient perspective, quantifying the extent to
which a disease impacts their health and functioning (Jones
et al., 2012). To establish the clinical relevance of a specific
improvement on an endpoint minimal clinically important
differences (MCIDs) are used. An MCID is the smallest
difference which patients perceive as beneficial and which
would mandate a change in patient treatment (Donohue,
2005). Establishing whether an improvement on a clinical
endpoint exceeds the MCID is a way to evaluate the clinical
relevance of a (new) pharmacological treatment (Make, 2007;
Koynova et al., 2013; Bartels et al., 2017).
In the last decade, multiple new medicines for the treatment
of chronic obstructive pulmonary disease (COPD) obtained
market access (CHMP, 2009; CHMP, 2012a; CHMP, 2012b;
CHMP, 2014). Assessment of new COPD medicines includes the
evaluation of effects on several efficacy endpoints, including
airway obstruction, dyspnea, health status, and exacerbations.
Frequently used parameters are forced expiratory volume in 1 sec
(FEV1), Transition Dyspnea Index (TDI) and St. George’s
Respiratory Questionnaire (SGRQ) for airway obstruction,
dyspnea and health status respectively (CHMP, 2009; CHMP,
2012a; CHMP, 2012b; CHMP, 2012c; CHMP, 2014). Although
FEV1 is an objective endpoint and highly reproducible (Cazzola
et al., 2008), it has a relatively poor correlation with symptoms
(Jones et al., 2012; Singh, 2017). PROs like dyspnea and health
status might better reflect the impact of the disease on COPD
patient’s daily life. Improvements of 100 ml, one units and four
units are validated MCIDs for FEV1, TDI, and SGRQ,
respectively (Donohue, 2005; Make, 2007; Cazzola et al., 2008;
Jones et al., 2014). Although these values are widely adopted,
some debate about the acceptability of these MCIDs exists,
especially for FEV1 (Donohue, 2005). Values up to 140 ml are
suggested as MCID for FEV1 (Cazzola et al., 2008). There is no
clear MCID for the evaluation of exacerbations (Chapman et
al., 2013).
Since FEV1, TDI, and SGRQ and their corresponding MCIDs
are used by registration authorities for the evaluation of clinical
efficacy of new medicines for the treatment of COPD, they are of
crucial importance for the market access of these new medicines.in.org 2Physicians and other healthcare professionals who prescribe (or
advise about) those medicines have to rely on the assessment of
new medicines by registration authorities. It is therefore of
particular interest to know their opinions about the endpoints
and MCIDs used in the assessment of clinical relevance of new
medicines. Although expert-opinions can be included in the
establishment of an MCID (in addition to the use of statistical
and anchor-based approaches) (Beaton et al., 2002; Make, 2007),
it is to our knowledge unknown how healthcare professionals
assess the clinical importance of endpoints and their MCIDs
used for new COPD medicines. The aims of this study are
therefore: 1) to investigate which efficacy endpoints healthcare
professionals consider clinically relevant in the assessment of
new medicines for COPD, and 2) to investigate which MCIDs
healthcare professionals consider relevant for the frequently used
endpoints FEV1, TDI, and SGRQ.MATERIALS AND METHODS
Background
Airway obstruction (measured by FEV1), dyspnea (measured by
TDI), and health status (measured by SGRQ) are important
efficacy endpoints in the assessment of new medicines for COPD
(CHMP, 2012c). FEV1 is the volume of air that is forcibly exhaled
in the 1st second. The trough (pre-bronchodilator) FEV1 is most
commonly used in clinical trials evaluating the efficacy of COPD
medicines (Donohue, 2005). A commonly used MCID for trough
FEV1 is 100 ml (Donohue, 2005; Make, 2007; Cazzola et al., 2008;
Jones et al., 2014). TDI is a validated evaluative instrument that
measures changes in the severity of dyspnea by grading
functional impairment, magnitude of task and magnitude of
effort. Each parameter is graded from -3 to +3, adding up to a
total score ranging from -9 to +9 (Cazzola et al., 2008). The
MCID is 1 unit (Donohue, 2005; Make, 2007; Cazzola et al., 2008;
Jones et al., 2014). SGRQ has been developed to measure health
status in patients with respiratory disease. It is a self-
administered questionnaire that measures health status in the
subdomains symptoms, activity and impacts, with a total score
ranging from 0 to 100 (Cazzola et al., 2008; Jones et al., 2012). A
difference of four units is considered clinically relevant
(Donohue, 2005; Make, 2007; Cazzola et al., 2008; Jones
et al., 2014).
Design
This investigation was part of a more extensive online survey
about the opinion of Dutch healthcare professionals regardingFebruary 2020 | Volume 10 | Article 1519
Dankers et al. Endpoints and MCIDs for COPD Medicinesthe clinical relevance of new medicines for the treatment of
diabetes mellitus type 2 (T2DM) and COPD. No ethical approval
was needed. According to the Dutch legislation, neither
obtaining informed consent nor approval by a medical ethics
committee is obligatory for carrying out research among
healthcare professionals that does not include patient data.
Participants
Participants for the online survey were obtained from the
Customer relationship management (CRM) of the Dutch
Institute for Rational Use of Medicine (IRUM). This CRM has
multiple purposes, but is predominantly used for sending
newsletters and information about the IRUMs activities. The
CRM contained 7,731 email addresses of Dutch healthcare
professionals (predominantly physicians, pharmacists, practice
nurses, respiratory nurses, and diabetes nurses).
Data Collection
The invitation to fill out the questionnaire was sent by email
(with a link to the questionnaire) on 15 November 2016. The
online survey was closed two weeks later. All healthcare
professionals received one reminder after 1 week. Participants
did not receive a financial compensation, although every 10th
participant was offered a free online accredited medicine course.
Questionnaire and Measurements
The full questionnaire consisted of 39 questions, among them 19
questions about new medicines for COPD. Responders were first
asked for their profession. Next, they were asked whether they
were involved in the management of patients with T2DM or
COPD in their daily clinical practice. Only healthcare
professionals working with COPD patients were asked to fill
out the COPD section of the questionnaire.
The content of the COPD section of the questionnaire was
based on the requirements for clinical trials for new COPD
medicines, as described in the Guideline on clinical investigation
of medicinal products in the treatment of COPD (CHMP, 2012c)
and the MCIDs mentioned in the public assessment reports of
new medicines for COPD (CHMP, 2009; CHMP, 2012a; CHMP,
2012b; CHMP, 2014).
The COPD section of the questionnaire consisted of three
parts. The first part investigated the healthcare professionals
preferred efficacy endpoints for the assessment of clinical
relevance of new COPD medicines. Healthcare professionals
were first informed about the need of efficacy endpoints in
clinical trials and then asked which efficacy endpoints they
considered clinically relevant for the assessment of new COPD
medicines. All questions were open-ended in order to enhance
the chance of getting reliable and sincere answers.
The second part investigated cut-off values for clinical
relevance for FEV1, TDI, and SGRQ. Healthcare professionals
were informed about these endpoints and asked for a cut-off
value for clinical relevance compared to placebo. All questions
were open-ended. The MCIDs for FEV1, TDI, and SGRQ were
not mentioned before, in order to stimulate healthcare
professionals to base their answer on their own clinicalFrontiers in Pharmacology | www.frontiersin.org 3experience without being influenced by the validated MCIDs.
Since TDI and SGRQ are not routinely used in daily clinical
practice in the Netherlands, the questionnaire gave a brief
description of these endpoints, including the range of those
scales. This enabled responders to estimate a clinically relevant
difference, regardless of their familiarity with those parameters.
The third part about safety endpoints was not included in
this analysis.
The online survey was programmed in NetQuestionnaire and
pre-tested by three general practitioners, two pharmacists
and three practice nurses for reasons of understandability and
content. Since they experienced more difficulties with the COPD
section compared to the T2DM section, the T2DM section was
positioned before the COPD section to enhance the overall
response rate.
Data Analysis
Responders were categorized by profession (physician,
pharmacist, practice nurse, and other). The group “other” was
excluded from further analysis. Responders who were both a
physician and pharmacist were analyzed as physicians. All different
types of nurses (for example, practice nurses, respiratory nurses,
and nurse practitioners) were analyzed together as practice nurses.
After collection of the endpoints mentioned by the
responders, six different categories of endpoints based on
Global strategy for prevention, diagnosis and management of
COPD 2019 report [Global Initiative for Chronic Obstructive
Lung Disease (GOLD), 2019] were defined. Those categories
were 1) exacerbations (including hospital admissions, infections,
use of antibiotics and oral steroids), 2) airway obstruction
(including parameters used to define airway obstruction like
FEV1), 3) health status (including quality of life, disease burden,
Clinical COPD Questionnaire (CCQ) wellbeing and daily
functioning), 4) respiratory symptoms (including dyspnea,
cough, Medical Research Council (MRC) dyspnea scale, use of
short-acting bronchodilators), 5) exercise intolerance (including
condition, physical activity), 6) mortality, and 7) other (including
morbidity, oxygen dependency or saturation, and adverse
events). Subsequently, all answers were categorized by two
researchers (based on consensus) and frequencies were
calculated. Some healthcare professionals mentioned the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) status as preferred endpoint. Since GOLD includes
airway obstruction, exacerbations and health status [Global
Initiative for Chronic Obstructive Lung Disease (GOLD),
2019], each answer that mentioned GOLD was counted into
these three categories. The categorization was verified by one
independent researcher.
All cut-off values in open text fields were recoded into numeric
variables. Impossible values for TDI and SGRQ (i.e., values
exceeding the parameter range) were excluded. Based on expert
opinions, FEV1 values > 0 and < 1 ml and FEV1 values > 1,499 ml
were considered implausible and therefore also excluded, as were
values in other units than asked (e.g., percentages instead of
milliliters). Ranges (e.g., 50–75) were converted to averages
(e.g., 67.5). Cut-off values for FEV1, TDI and SGRQ wereFebruary 2020 | Volume 10 | Article 1519
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Results were considered significant when p < 0.05.
All results were analyzed with IBM SPSS Statistics 24.RESULTS
A total of 556 responders (6.6%) started the questionnaire. Only
healthcare professionals working with COPD patients in daily
practice were included in this analysis. The final population
consisted of 227 healthcare professionals (88 physicians, 107
pharmacists, and 27 practice nurses), resulting in a response rate
of 2.9% (Figure 1). The group of 88 physicians contained two
physicians who were also pharmacists and one dispensing general
practitioner. Those were analyzed solely as physicians. Among the
group of 27 practice nurses were 21 practice nurses, one respiratory
nurse, one physician assistant, one nurse practitioner, one trainee
nurse practitioner, one geriatric nurse, and one practice nurse who
was also a respiratory nurse and diabetes nurse. Those were
analyzed together as practice nurses.
Endpoints
196 healthcare professionals mentioned their efficacy endpoints
of preference. The most frequently mentioned endpoints were
exacerbations (51.0%), airway obstruction (46.9%), and health
status (44.9%) (Table 1).
MCIDs
Healthcare professionals were asked for a cut-off value that defined
clinical relevance for FEV1, TDI, and SGRQ. For both TDI andFrontiers in Pharmacology | www.frontiersin.org 4SGRQ, cut-off values according to healthcare professionals (2.5
and 11.0 units, respectively) were significantly higher than the
MCIDs used by the European Medicines Agency (EMA) (one
unit and four units, respectively) (Table 2). Mean differences for
TDI and SGRQ compared to MCID’s were 1.5 (95% CI = 1.3–1.8,
p < 0.001) and 7.0 (95% CI = 5.1–8.8, p < 0.001). Pharmacists
mentioned the highest cut-off values for both TDI (2.8 units;
followed by 2.4 units by physicians and 2.2 units by practice
nurses) and SGRQ (12.2 units, followed by 11.5 units by practice
nurses and 9.5 units by physicians).
The mean cut-off value for FEV1 (102.2 ml) according to
healthcare professionals was comparable to the MCID (100 ml),
mean difference 2.2 ml (95% CI = -19.9–24.3, p = 0.84). Mean
cut-off values according to pharmacists, physicians and practice
nurses were 100.8 ml, 115.3 ml, and 72.1 ml, respectively. None
of these cut-off values were significantly different from
the MCID.DISCUSSION
This study investigated which endpoints and MCIDs healthcare
professionals considered clinically relevant for the evaluation of
the efficacy of new medicines for COPD. Dutch healthcare
professionals seem slightly more critical than registration
authorities in the assessment of the clinical relevance of those
new medicines. Although the preferred endpoints roughly
correspond with the ones used in clinical trials, healthcare
professionals prefer higher cut-off values for clinical relevance
for TDI and SGRQ than the MCIDs used by registration
authorities. This stricter view of clinical relevance is not seen
for airway obstruction, since the average cut-off value for FEV1
was comparable to the MCID. In general, physicians and practice
nurses were less critical than pharmacists. This may display a
difference in the clinical experience of healthcare professionals.
Practice nurses and physicians more often see patients and
measure endpoints like airway obstruction, dyspnea and health
status than pharmacists. That might enhance their ability of
estimating the expected medicine-induced improvement.
To our knowledge, this is the first study that specifically
investigated the opinions of healthcare professionals about the
endpoints and MCIDs used for the assessment of clinical efficacy
of new COPD medicines. Expert opinions on the MCID for
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topic were generally higher than the MCID of 100 ml and thus
also higher than the cut-off value for FEV1 found in our
investigation (Donohue, 2005).
The differences between the cut-off values found in this
investigation and established MCIDs might reflect the challenges
with MCIDs as stated in other publications (Donohue, 2005; Kiley
et al., 2005; Jones et al., 2014). Factors such as heterogeneity in
population and disease, trial duration, Hawthorne effects,
withdrawal rates, and baseline disease severity may affect the size
of benefit relative to the MCID (Kiley et al., 2005; Jones et al., 2014).
It is therefore suggested that MCIDs should be used as an indicative
value rather than as an absolute cut-off point (Jones et al., 2014). The
EMA, however, uses MCIDs to define the clinical relevance of new
medicines. The cut-off values found in our study would have
consequences for the evaluation of the clinical relevance of new
COPDmedicines. Multiple new (single-agent) inhalation medicines
(aclidinium, glycopyrronium, indacaterol, and umeclidinium) for
the treatment of COPD have been approved in Europe in the last
decade. According to the EMA assessment of those medicines,
roughly 50% of all improvements on FEV1, TDI, and SGRQ
exceeded the MCID and were thus considered clinically relevant
(CHMP, 2009; CHMP, 2012a; CHMP, 2012b; CHMP, 2014). When
using the mean cut-off values found in the current study, instead of
the MCIDs, none of the improvements on TDI and SGRQ would
still have been clinically relevant. A new medicine that is considered
“clinically relevant” by registration authorities does, therefore, not
necessarily reflect healthcare professionals’ views on clinical
relevance. Since healthcare professionals have a stricter view of
cut-off values for clinical relevance, defining clinical relevance by use
of MCIDs might lead to overestimation of the expected
treatment benefit.
Our results indicate that healthcare professionals consider
exacerbations as the most important endpoint. Evaluation of the
clinical importance of a reduction in exacerbations was not
included in this investigation. Although evaluation of
exacerbations is also part of the assessment procedure of new
COPD medicines, there is no specific MCID used (CHMP, 2009;
CHMP, 2012a; CHMP, 2012b; CHMP, 2014). Defining an MCID
for COPD exacerbations is problematic, because the impact of
exacerbations is influenced dramatically by the used definition ofFrontiers in Pharmacology | www.frontiersin.org 5(the severity of) an exacerbation and the influence of baseline
status (Chapman et al., 2013). The use of exacerbation-free time
instead of frequency (or severity) of exacerbations might better
reflect the burden of exacerbations in COPD patients (Boer et al.,
2018). Future work should reveal the clinical relevance of a
reduction in incidence or severity of exacerbations, or the
increase of exacerbation-free time.
This study only included the assessment of the efficacy of new
medicines for COPD. This is only a part of the assessment of new
medicines, since safety and ease of use are also of clinical
importance (CHMP, 2009; CHMP, 2012a; CHMP, 2012b;
CHMP, 2014). Our investigation did also not include patient
preferences on endpoints and MCIDs. A comprehensive
literature review of patient preferences for the management of
COPD revealed that the most important issues to patients with
severe disease were symptom control, impact of disease on daily
life, and positive relationship with the primary caregiver (Bereza
et al., 2015). Another study reported the most reported ideal
treatment factors based on interviews with 72 patients with
asthma or COPD. These patients mentioned improved sleep,
speed of action, and length of relief as most important aspects of
treatment (Svedsater et al., 2017). Patients perspectives on
MCIDs are to our knowledge still unknown.
This investigation was meant as a first study to explore the
opinion of different healthcare professionals (physicians,
pharmacists, and practice nurses) on clinical relevance of
endpoints and cut-off values. Since this study is based on the
opinion of healthcare professionals working with COPD patients
in daily practice, it provides a clear view of how clinical relevance
of new medicines is considered in the daily practice of physicians,
pharmacists and practice nurses. The main strength of this
investigation is the exploratory and open character which was
stimulated by the questionnaire with open-ended answers. There
are, nonetheless, some limitations of this study. First, the results
cannot be generalized to all Dutch healthcare professionals. Since
the IRUM’s CRM was used, only healthcare professionals who
were somehow interested in pharmaceutical care were included in
this study. Second, approximately half of the responders were
pharmacists. In general, they will have less clinical experience than
physicians and practice nurses. The overrepresentation of
pharmacists could have influenced the mean cut-off values.TABLE 2 | Cut-off values for FEV1, TDI, and SGRQ according to healthcare professionals, compared to the corresponding MCID.
n Mean (SD) Mean difference compared to MCID (95%CI) p
FEV1 (ml) All 105 102.2 (114.1) 2.2 (-19.9–24.3) 0.84
MCID = 100 ml Physicians 44 115.3 (108.8) 15.3 (-17.8–48.3) 0.36
Pharmacists 44 100.8 (133.6) 0.75 (-39.9–41.4) 0.97
Practice nurses 17 72.1 (57.8) -27.9 (-57.6–1.9) 0.064
TDI (unit) All 109 2.5 (1.4) 1.5 (1.3–1.8) <0.001*
MCID = 1 unit Physicians 44 2.4 (1.3) 1.4 (1.0–1.7) <0.001*
Pharmacists 53 2.8 (1.5) 1.8 (1.4–2.2) <0.001*
Practice nurses 12 2.2 (1.6) 1.2 (0.16–2.2) 0.027*
SGRQ (unit) All 119 11.0 (10.1) 7.0 (5.1–8.8) <0.001*
MCID = 4 units Physicians 50 9.5 (6.4) 5.5 (3.7–7.3) <0.001*
Pharmacists 56 12.2 (11.9) 8.2 (5.0–11.3) <0.001*
Practice nurses 13 11.5 (13.4) 7.5 (-0.56–15.6) 0.065February 2020 | Volume 10 | Arti* Statistically significant different compared to MCID, based on one-sample T-test. Results were considered significant when p < 0.05.cle 1519
Dankers et al. Endpoints and MCIDs for COPD MedicinesHowever, the analysis of the cut-off values per profession showed
that the results of the different professions were generally in line
with each other. Third, the response rate was poor, with only 6.6
percent response to the general questionnaire and 2.9 percent to
the COPD section. The number of responders that completed the
questions about cut-off values was even lower. There are some
possible explanations for this. Since the healthcare professionals
were enrolled in a CRM instead of a research panel, they did not
routinely participate in investigations and were not used to be
approached for research via this panel. Another contributing
factor to the low response was the fact that this research was
part of a more extensive investigation towards the opinion of
healthcare professionals about new medicines. A substantial
number of healthcare professionals dropped out before the
COPD section. However, unless the poor response rate, there
was still a considerable number of healthcare professionals
available for analysis. Fourth, the questions about cut-off values
for TDI and SGRQ might have been fairly difficult to answer,
since these instruments are not routinely used in Dutch clinical
practice. This seems to be reflected by the wide range of cut-off
values for clinical relevance. To maximize the probability of
getting reliable results, the questionnaire referred to the range of
scores for TDI and SGRQ. This enabled healthcare professionals
unfamiliar with these scales to estimate a clinically relevant
difference. However, this does not completely rule out the
possibility of inaccuracy in the mentioned cut-off values for TDI
and SGRQ.Frontiers in Pharmacology | www.frontiersin.org 6Despite these limitations, this study suggests that healthcare
professionals are more critical than registration authorities in
defining the clinical relevance of the efficacy of new medicines
for the treatment of COPD. Larger and more representative ad
hoc trials are needed to focus the topic and confirm these
results. In the meantime, the established MCIDs should be
used with caution, since new medicines that exceed the MCID
do not necessarily meet the expectations of clinical relevance
according to healthcare professionals. Defining clinical
relevance by using MCIDs might, therefore, lead to
overestimation of the expected treatment benefit of new
COPD medicines by healthcare professionals.DATA AVAILABILITY STATEMENT
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